Advertisement

Topics

NT-ProBNP-guided treatment no benefit in high-risk HFrEF

09:00 EDT 23 Aug 2017 | Medical Xpress

(HealthDay)—For high-risk patients with heart failure and reduced ejection fraction (HFrEF), an amino-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided treatment strategy does not improve clinical outcomes versus usual care, according to a study published in the Aug. 22/29 issue of the Journal of the American Medical Association.

Original Article: NT-ProBNP-guided treatment no benefit in high-risk HFrEF

NEXT ARTICLE

More From BioPortfolio on "NT-ProBNP-guided treatment no benefit in high-risk HFrEF"

Advertisement
Quick Search
Advertisement
Advertisement